Abstract:Rev. Bras. Cir. Cardiovasc., 5(1) : 54-60, 1990.RESUMO : A técnica de Imunocitomonitorização (CIM -Cytological and Immunologic Monitoring), fundamenta-se na avaliação de mudanças nas subpopulaçóes de linfócitos e seus precursores celulares, durante o processo rejeição aguda. O método avalia a ativação precoce pela contagem do número de: linfócitos ativados, linfoblastos e prolinfócitos (aqui chamados em conjunto de linfócitos ativos), quando esses se apresentam acima do limite superior normal. Utilizamos essa … Show more
“…To complete this evaluation we made an analysis of the pre-rejection lymphocytic morphological variations, cytoimmune monitoring, as well as early diagnosis of bacteremia and infectious processes by means of cyto-bacterial monitoring [12,13].…”
Object: This paper aims to define the prescribility (therapeutic efficacy and bio-safety) of generic microemulsion Cyclosporin (Sigmasporin Microral®). Method: Casuistic: Twenty heart transplantation patients, 13 males and 7 females, with a mean age of 49.6 years, began immunosuppression treatment with generic microemulsion cyclosporin (Sigmasporin Microral®). They underwent clinical and laboratory evaluation during a minimum of three months. Procedures included clinic evaluation with electro and echocardiogram, endomyocardial biopsy, routine biochemical and hematological tests. Results: The mean follow-up was 10 months with a maximum of 16 months. A total of 151 endomyocardial biopsies were evaluated: 31.7% were degree 0, 43.7% 1a and 23.1% 1b. We had only one case of acute clinical rejection confirmed by biopsy as IIIa, and one patient with mediastinitis, both of whom had a good evolution. The mean cyclosporin blood level was 303 Ng/mL. All other parameters also showed a good evolution. Conclusion: Generic microemulsion cyclosporin (Sigmasporin Microral®) shows therapeutic efficacy and an excellent bio-safety profile. Its Prescribility is confirmed.
“…To complete this evaluation we made an analysis of the pre-rejection lymphocytic morphological variations, cytoimmune monitoring, as well as early diagnosis of bacteremia and infectious processes by means of cyto-bacterial monitoring [12,13].…”
Object: This paper aims to define the prescribility (therapeutic efficacy and bio-safety) of generic microemulsion Cyclosporin (Sigmasporin Microral®). Method: Casuistic: Twenty heart transplantation patients, 13 males and 7 females, with a mean age of 49.6 years, began immunosuppression treatment with generic microemulsion cyclosporin (Sigmasporin Microral®). They underwent clinical and laboratory evaluation during a minimum of three months. Procedures included clinic evaluation with electro and echocardiogram, endomyocardial biopsy, routine biochemical and hematological tests. Results: The mean follow-up was 10 months with a maximum of 16 months. A total of 151 endomyocardial biopsies were evaluated: 31.7% were degree 0, 43.7% 1a and 23.1% 1b. We had only one case of acute clinical rejection confirmed by biopsy as IIIa, and one patient with mediastinitis, both of whom had a good evolution. The mean cyclosporin blood level was 303 Ng/mL. All other parameters also showed a good evolution. Conclusion: Generic microemulsion cyclosporin (Sigmasporin Microral®) shows therapeutic efficacy and an excellent bio-safety profile. Its Prescribility is confirmed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.